Who are TG Therapeutics, Inc.'s main suppliers?

TG Therapeutics, Inc. (TGTX) key suppliers include: CERTAIN-SUBSIDIARIES-OF-THE-BORROWER, MaxCyte, Inc., Precision BioSciences, Inc., Precision BioSciences, Inc.. View the full supplier network at chainsifter.com/chain/TGTX.

Who are TG Therapeutics, Inc.'s major customers?

TG Therapeutics, Inc. (TGTX) key customers include: NEURAXPHARM, CUSTOMER-1, CUSTOMER-2, CUSTOMER-3, CUSTOMER-4 and 5 more. View the full customer network at chainsifter.com/chain/TGTX.

What sector is TG Therapeutics, Inc. in?

TG Therapeutics, Inc. (TGTX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

TGTX Supply Chain: TG Therapeutics, Inc. Supplier List & 17 Relationships

4Suppliers

10Customers

3Debt Items

20Related Chains

TG Therapeutics, Inc. Suppliers

Ticker	Name	Confidence	Evidence
CERTAIN-SUBSIDIARIES-OF-THE-BORROWER	CERTAIN-SUBSIDIARIES-OF-THE-BORROWER	90%	certain subsidiaries of the Borrower, as guarantors, the lenders party thereto and Blue Owl Capital Corporation, as administrative agent
MXCT	MaxCyte, Inc.	85%	Reciprocal relationship from MXCT graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from MXCT g…
DTIL	Precision BioSciences, Inc.	72%	oduct candidates. The Company may seek significant additional financing in the future to support strategic initiatives and its ongoing and planned operations. The Company's common stock is quoted on …
DTIL	Precision BioSciences, Inc.	72%	Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: oduct candidates. The Company may seek significant additional financing in the future to support strategic initiative…

TG Therapeutics, Inc. Customers

Ticker	Name	Confidence	Evidence
NEURAXPHARM	NEURAXPHARM	92%	License, milestone, royalty and other revenue consist primarily of recognition of consideration received under the ex-U.S. commercialization agreement (the Commercialization Agreement) with Neuraxpharm.
CUSTOMER-1	CUSTOMER-1	90%	Three months ended March 31, 2026 Customer 1 42 % 39 %
CUSTOMER-2	CUSTOMER-2	90%	Three months ended March 31, 2026 Customer 2 27 % 34 %
CUSTOMER-3	CUSTOMER-3	90%	Three months ended March 31, 2026 Customer 3 20 % 16 %
CUSTOMER-4	CUSTOMER-4	90%	Three months ended March 31, 2026 Customer 4 9 % 11 %
DTIL	Precision BioSciences, Inc.	72%	Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from TGTX graph: oduct candidates. The Company may s…
DTIL	Precision BioSciences, Inc.	72%	oduct candidates. The Company may seek significant additional financing in the future to support strategic initiatives and its ongoing and planned operations. The Company's common stock is quoted on …
MXCT	MaxCyte, Inc.	72%	Reciprocal relationship from MXCT graph: ory approval for all or any product candidates covered by their SPL agreements with us, in which case we will not receive the full potential precommercial mil…
NVSEF	Novartis AG	72%	all rights under the Commercialization Agreement for a period of two years in the event of a change in control of TG. 13 Table of Contents TG-1701 (BTK inhibitor) In January 2018, we entered into…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from TGTX graph: all rights under the Commercialization Agreement for a period of two years in the event of a change in control of TG…

TG Therapeutics, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
TGTX-DEBT-12967	Warrants outstanding: 147058	90%	xbrl warrant detail from xbrl 2023-12-31.
TGTX-DEBT	Debt stack $753.6M	90%	Market cache reports total debt of $753.6M.
TGTX-DEBT-12968	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2023-12-31.

TG Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for TG Therapeutics, Inc..

TG Therapeutics, Inc. Ownership

Holder	Name	Confidence	Evidence
TGTX-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 368 tracked holders.

TG Therapeutics, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
DB	Deutsche Bank Aktiengesellschaft	100.00	2
TMO	Thermo Fisher Scientific Inc.	100.00	2
CLLS	Cellectis S.A.	100.00	2
CELU	Celularity Inc.	100.00	2
ENGN	enGene Therapeutics Inc.	100.00	2
FISI	Financial Institutions, Inc.	100.00	2
ALEC	Alector, Inc.	100.00	2
CMPS	COMPASS Pathways plc	100.00	2
BIO	Bio-Rad Laboratories, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
BBIO	BridgeBio Pharma, Inc.	100.00	2
HBIO	Harvard Bioscience, Inc.	100.00	2
IRON	Disc Medicine, Inc.	100.00	2
SVRA	Savara Inc.	100.00	2
ALT	Altimmune, Inc.	100.00	2
DTIL	Precision BioSciences, Inc.	100.00	1	['customer', 'supplier']
DERM	Journey Medical Corporation	100.00	2
ANAB	AnaptysBio, Inc.	100.00	2
BCYC	Bicycle Therapeutics plc	100.00	2
KURA	Kura Oncology, Inc.	100.00	2

TG Therapeutics, Inc. Supply Chain